APO Research
Talk to an analyst

APO RESEARCH · REPORT

Burosumab

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Burosumab Market Outlook and Growth Opportunities 2026

30 December 2025198 pages

Choose your research edition.

Industry ResearchBurosumab Industry Research Report 2026114 pages · $2,950 USDIndustry Growth & TrendsGlobal Burosumab Industry Growth and Trends Forecast to 203272 pages · $3,450 USDMarket StructureGlobal Burosumab Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032172 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Burosumab Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Burosumab Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Burosumab market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Burosumab is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Burosumab is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Burosumab is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Burosumab market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Burosumab market include Ultragenyx and Kyowa Kirin Co.,Ltd. among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Burosumab market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Burosumab and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Burosumab sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Burosumab market size, projected growth trends, production technologies, key applications, and end-use industries.

Burosumab Segment by Company

Ultragenyx

Kyowa Kirin Co.,Ltd.

Burosumab Segment by Type

10mg/mL

20mg/mL

30mg/mL

Burosumab Segment by Application

Minor Patients Over 1 Year Old

Adult Patients

Burosumab Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Burosumab status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Burosumab market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Burosumab significant trends, drivers, influence factors in global and regions.

6. To analyze Burosumab competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Burosumab market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Burosumab and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Burosumab.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Burosumab market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Burosumab industry.

Chapter 3: Detailed analysis of Burosumab manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Burosumab in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Burosumab in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Burosumab Industry Trends Table 2. Burosumab Industry Drivers Table 3. Burosumab Industry Opportunities and Challenges Table 4. Burosumab Industry Restraints Table 5. Global Burosumab Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Burosumab Revenue Share by Company (2021-2026) Table 7. Global Burosumab Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Burosumab Sales Volume Share by Company (2021-2026) Table 9. Global Burosumab Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Burosumab Company Ranking, (2024-2026) & (USD Million) Table 11. Global Burosumab Key Company Manufacturing Base & Headquarters Table 12. Global Burosumab Company, Product Type & Application Table 13. Global Burosumab Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Burosumab by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of 10mg/mL Table 18. Significant Companies of 20mg/mL Table 19. Significant Companies of 30mg/mL Table 20. Global Burosumab Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 21. Global Burosumab Sales Volume by Type (2021-2026) & (K Units) Table 22. Global Burosumab Sales Volume by Type (2027-2032) & (K Units) Table 23. Global Burosumab Sales Volume Share by Type (2021-2026) Table 24. Global Burosumab Sales Volume Share by Type (2027-2032) Table 25. Global Burosumab Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Burosumab Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Burosumab Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Burosumab Sales Value Share by Type (2021-2026) Table 29. Global Burosumab Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Minor Patients Over 1 Year Old Table 31. Significant Companies of Adult Patients Table 32. Global Burosumab Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 33. Global Burosumab Sales Volume by Application (2021-2026) & (K Units) Table 34. Global Burosumab Sales Volume by Application (2027-2032) & (K Units) Table 35. Global Burosumab Sales Volume Share by Application (2021-2026) Table 36. Global Burosumab Sales Volume Share by Application (2027-2032) Table 37. Global Burosumab Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Burosumab Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Burosumab Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Burosumab Sales Value Share by Application (2021-2026) Table 41. Global Burosumab Sales Value Share by Application (2027-2032) Table 42. Global Burosumab Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 43. Global Burosumab Sales by Region (2021-2026) & (K Units) Table 44. Global Burosumab Sales Market Share by Region (2021-2026) Table 45. Global Burosumab Sales by Region (2027-2032) & (K Units) Table 46. Global Burosumab Sales Market Share by Region (2027-2032) Table 47. Global Burosumab Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Burosumab Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Burosumab Sales Value Share by Region (2021-2026) Table 50. Global Burosumab Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Burosumab Sales Value Share by Region (2027-2032) Table 52. Global Burosumab Market Average Price (US$/Unit) by Region (2021-2026) Table 53. Global Burosumab Market Average Price (US$/Unit) by Region (2027-2032) Table 54. Global Burosumab Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Global Burosumab Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Burosumab Sales by Country (2021-2026) & (K Units) Table 57. Global Burosumab Sales Market Share by Country (2021-2026) Table 58. Global Burosumab Sales by Country (2027-2032) & (K Units) Table 59. Global Burosumab Sales Market Share by Country (2027-2032) Table 60. Global Burosumab Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Burosumab Sales Value Market Share by Country (2021-2026) Table 62. Global Burosumab Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Burosumab Sales Value Market Share by Country (2027-2032) Table 64. Ultragenyx Company Information Table 65. Ultragenyx Business Overview Table 66. Ultragenyx Burosumab Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 67. Ultragenyx Burosumab Product Portfolio Table 68. Ultragenyx Recent Development Table 69. Kyowa Kirin Co.,Ltd. Company Information Table 70. Kyowa Kirin Co.,Ltd. Business Overview Table 71. Kyowa Kirin Co.,Ltd. Burosumab Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. Kyowa Kirin Co.,Ltd. Burosumab Product Portfolio Table 73. Kyowa Kirin Co.,Ltd. Recent Development Table 74. Key Raw Materials Table 75. Raw Materials Key Suppliers Table 76. Burosumab Distributors List Table 77. Burosumab Customers List Table 78. Research Programs/Design for This Report Table 79. Authors List of This Report Table 80. Secondary Sources Table 81. Primary Sources List of Figures Figure 1. Burosumab Product Image Figure 2. Global Burosumab Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Burosumab Sales Value (2021-2032) & (US$ Million) Figure 4. Global Burosumab Sales (2021-2032) & (K Units) Figure 5. Global Burosumab Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Burosumab Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. 10mg/mL Image Figure 10. 20mg/mL Image Figure 11. 30mg/mL Image Figure 12. Global Burosumab Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 13. Global Burosumab Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Burosumab Sales Volume Share by Type (2021-2032) Figure 15. Global Burosumab Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Burosumab Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Burosumab Sales Value Share by Type (2021-2032) Figure 18. Minor Patients Over 1 Year Old Image Figure 19. Adult Patients Image Figure 20. Global Burosumab Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 21. Global Burosumab Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Burosumab Sales Volume Share by Application (2021-2032) Figure 23. Global Burosumab Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Burosumab Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Burosumab Sales Value Share by Application (2021-2032) Figure 26. Global Burosumab Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 27. Global Burosumab Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Burosumab Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Burosumab Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Burosumab Sales Value (2021-2032) & (US$ Million) Figure 31. North America Burosumab Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Burosumab Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Burosumab Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Burosumab Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Burosumab Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Burosumab Sales Value (2021-2032) & (US$ Million) Figure 37. South America Burosumab Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Burosumab Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Burosumab Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Burosumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Burosumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Burosumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Burosumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Burosumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Burosumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Burosumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Burosumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Burosumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Burosumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Burosumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Burosumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Burosumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Burosumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Burosumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Burosumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Burosumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Burosumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Burosumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Burosumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Burosumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Burosumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Burosumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Burosumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Burosumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Burosumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Burosumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Burosumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Burosumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Burosumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Burosumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Burosumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Burosumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Burosumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Burosumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Burosumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Burosumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Burosumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Burosumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Burosumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Burosumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Burosumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Burosumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Burosumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Burosumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Burosumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Burosumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Burosumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Burosumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Burosumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Burosumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Burosumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Burosumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Burosumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Burosumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Burosumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Burosumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Burosumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Burosumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Burosumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Burosumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Burosumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Burosumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Burosumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Burosumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Burosumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Burosumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Burosumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Burosumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Burosumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Burosumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Burosumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Burosumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Burosumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Burosumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Burosumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Burosumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Burosumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Burosumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Burosumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Burosumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Burosumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Burosumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Burosumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Burosumab Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Burosumab Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • 10mg/mL
  • 20mg/mL
  • 30mg/mL
Applications
  • Minor Patients Over 1 Year Old
  • Adult Patients
Companies covered
  • Ultragenyx
  • Kyowa Kirin Co.,Ltd.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Burosumab Sales Value (2021-2032)
  4. 1.2.2 Global Burosumab Sales Volume (2021-2032)
  5. 1.2.3 Global Burosumab Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Burosumab Market Dynamics
  1. 2.1 Burosumab Industry Trends
  2. 2.2 Burosumab Industry Drivers
  3. 2.3 Burosumab Industry Opportunities and Challenges
  4. 2.4 Burosumab Industry Restraints
3 Burosumab Market by Company
  1. 3.1 Global Burosumab Company Revenue Ranking in 2025
  2. 3.2 Global Burosumab Revenue by Company (2021-2026)
  3. 3.3 Global Burosumab Sales Volume by Company (2021-2026)
  4. 3.4 Global Burosumab Average Price by Company (2021-2026)
  5. 3.5 Global Burosumab Company Ranking (2024-2026)
  6. 3.6 Global Burosumab Company Manufacturing Base and Headquarters
  7. 3.7 Global Burosumab Company Product Type and Application
  8. 3.8 Global Burosumab Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Burosumab Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Burosumab Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Burosumab Market by Type
  1. 4.1 Burosumab Type Introduction
  2. 4.1.1 10mg/mL
  3. 4.1.2 20mg/mL
  4. 4.1.3 30mg/mL
  5. 4.2 Global Burosumab Sales Volume by Type
  6. 4.2.1 Global Burosumab Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Burosumab Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Burosumab Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Burosumab Sales Value by Type
  10. 4.3.1 Global Burosumab Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Burosumab Sales Value by Type (2021-2032)
  12. 4.3.3 Global Burosumab Sales Value Share by Type (2021-2032)
5 Burosumab Market by Application
  1. 5.1 Burosumab Application Introduction
  2. 5.1.1 Minor Patients Over 1 Year Old
  3. 5.1.2 Adult Patients
  4. 5.2 Global Burosumab Sales Volume by Application
  5. 5.2.1 Global Burosumab Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Burosumab Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Burosumab Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Burosumab Sales Value by Application
  9. 5.3.1 Global Burosumab Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Burosumab Sales Value by Application (2021-2032)
  11. 5.3.3 Global Burosumab Sales Value Share by Application (2021-2032)
6 Burosumab Regional Sales and Value Analysis
  1. 6.1 Global Burosumab Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Burosumab Sales by Region (2021-2032)
  3. 6.2.1 Global Burosumab Sales by Region: 2021-2026
  4. 6.2.2 Global Burosumab Sales by Region (2027-2032)
  5. 6.3 Global Burosumab Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Burosumab Sales Value by Region (2021-2032)
  7. 6.4.1 Global Burosumab Sales Value by Region: 2021-2026
  8. 6.4.2 Global Burosumab Sales Value by Region (2027-2032)
  9. 6.5 Global Burosumab Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Burosumab Sales Value (2021-2032)
  12. 6.6.2 North America Burosumab Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Burosumab Sales Value (2021-2032)
  15. 6.7.2 Europe Burosumab Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Burosumab Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Burosumab Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Burosumab Sales Value (2021-2032)
  21. 6.9.2 South America Burosumab Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Burosumab Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Burosumab Sales Value Share by Country, 2025 VS 2032
7 Burosumab Country-level Sales and Value Analysis
  1. 7.1 Global Burosumab Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Burosumab Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Burosumab Sales by Country (2021-2032)
  4. 7.3.1 Global Burosumab Sales by Country (2021-2026)
  5. 7.3.2 Global Burosumab Sales by Country (2027-2032)
  6. 7.4 Global Burosumab Sales Value by Country (2021-2032)
  7. 7.4.1 Global Burosumab Sales Value by Country (2021-2026)
  8. 7.4.2 Global Burosumab Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Burosumab Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Burosumab Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Burosumab Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Burosumab Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Burosumab Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Burosumab Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Burosumab Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Burosumab Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Burosumab Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Burosumab Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Burosumab Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Burosumab Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Burosumab Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Burosumab Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Burosumab Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Burosumab Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Burosumab Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Burosumab Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Burosumab Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Burosumab Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Burosumab Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Burosumab Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Burosumab Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Burosumab Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Burosumab Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Burosumab Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Burosumab Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Burosumab Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Burosumab Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Burosumab Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Burosumab Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Burosumab Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Burosumab Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Burosumab Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Burosumab Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Burosumab Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Burosumab Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Burosumab Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Burosumab Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Burosumab Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Burosumab Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Burosumab Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Burosumab Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Burosumab Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Burosumab Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Burosumab Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Burosumab Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Burosumab Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Burosumab Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Burosumab Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Burosumab Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Burosumab Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Burosumab Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Burosumab Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Burosumab Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Burosumab Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Burosumab Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Burosumab Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Burosumab Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Burosumab Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Burosumab Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Burosumab Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Burosumab Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Burosumab Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Burosumab Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Burosumab Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Burosumab Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Burosumab Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Burosumab Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Burosumab Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Burosumab Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Burosumab Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Burosumab Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Burosumab Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Burosumab Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Burosumab Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Burosumab Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Burosumab Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Burosumab Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Burosumab Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Burosumab Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Burosumab Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Burosumab Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Burosumab Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Ultragenyx
  2. 8.1.1 Ultragenyx Company Information
  3. 8.1.2 Ultragenyx Business Overview
  4. 8.1.3 Ultragenyx Burosumab Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Ultragenyx Burosumab Product Portfolio
  6. 8.1.5 Ultragenyx Recent Developments
  7. 8.2 Kyowa Kirin Co.,Ltd.
  8. 8.2.1 Kyowa Kirin Co.,Ltd. Company Information
  9. 8.2.2 Kyowa Kirin Co.,Ltd. Business Overview
  10. 8.2.3 Kyowa Kirin Co.,Ltd. Burosumab Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Kyowa Kirin Co.,Ltd. Burosumab Product Portfolio
  12. 8.2.5 Kyowa Kirin Co.,Ltd. Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Burosumab Value Chain Analysis
  2. 9.1.1 Burosumab Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Burosumab Sales Mode & Process
  6. 9.2 Burosumab Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Burosumab Distributors
  9. 9.2.3 Burosumab Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst